Potential of Neuroprotective Therapy in Parkinson’s Disease

[1]  P. Mecocci,et al.  Oxidative damage to mitochondrial DNA shows marked age‐dependent increases in human brain , 1993, Annals of neurology.

[2]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[3]  K. Kieburtz.  A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease , 1993, Annals of neurology.

[4]  H. Kimura,et al.  Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.

[5]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[6]  Y. Agid,et al.  The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures , 1992, Brain Research.

[7]  D. Greenberg,et al.  Antiparkinsonian drugs and in vitro excitotoxicity , 1992, Brain Research.

[8]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[9]  A. Kupsch,et al.  Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice , 1992, Brain Research.

[10]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[11]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[12]  F. Vaglini,et al.  MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates , 1992, Journal of neurochemistry.

[13]  C. Morris,et al.  Uptake and Distribution of Iron and Transferrin in the Adult Rat Brain , 1992, Journal of neurochemistry.

[14]  R. Lindsay,et al.  Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione System , 1992, Journal of neurochemistry.

[15]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[16]  Y. Mizuno,et al.  Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain , 1992, Journal of the Neurological Sciences.

[17]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[18]  David L. Felten,et al.  Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats , 1992, Neurobiology of Aging.

[19]  T. Chase,et al.  Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging , 1992, Neurology.

[20]  K. Sotaniemi,et al.  Selegiline as initial treatment in de novo parkinsonian patients , 1992, Neurology.

[21]  E. Neafsey,et al.  Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins , 1992, Brain Research.

[22]  L. Loeb,et al.  8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. , 1992, The Journal of biological chemistry.

[23]  D. Mash,et al.  21‐Aminosteroids Interact with the Dopamine Transporter to Protect Against 1‐Methyl‐4‐Phenylpyridinium‐Induced Neurotoxicity , 1992, Journal of neurochemistry.

[24]  S. Ohta,et al.  1‐Methyl‐ 1,2,3,4‐Tetrahydroisoquinoline, Decreasing in 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Mouse, Prevents Parkinsonism‐Like Behavior Abnormalities , 1991, Journal of neurochemistry.

[25]  T. Ozawa,et al.  Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.

[26]  F. Jiménez-Jiménez,et al.  Acute Effects of 1‐Methyl‐4‐Phenyl‐1, 2, 3, 6‐Tetrahydropyridine in a Model of Rat Designated a Poor Metabolizer of Debrisoquine , 1991, Journal of neurochemistry.

[27]  J. Rinne,et al.  Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease , 1991, Neurology.

[28]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[29]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[30]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[31]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[32]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[33]  E. Neafsey,et al.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Orrenius,et al.  The role of Ca2+ in cell killing. , 1990, Chemical research in toxicology.

[35]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[36]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[37]  K. Ohno,et al.  Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. , 1990, Biochemical and biophysical research communications.

[38]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[39]  I. Romslo,et al.  The role of transferrin in the mechanism of cellular iron uptake. , 1990, The Biochemical journal.

[40]  K. Ohno,et al.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. , 1990, Biochemical and biophysical research communications.

[41]  C. Morris,et al.  Brain transferrin receptors and the distribution of cytochrome oxidase. , 1990, Biochemical Society Transactions.

[42]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[43]  H. Teräväinen.  Selegiline in Parkinson's disease , 1990, Acta neurologica Scandinavica.

[44]  E. Neafsey,et al.  Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products , 1990, Brain Research.

[45]  M. Naoi,et al.  N-methylisoquinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic l-amino acid decarboxylase and monoamine oxidase , 1989, Neurochemistry International.

[46]  S. Fahn.  The Endogenous Toxin Hypothesis of the Etiology of Parkinson's Disease and a Pilot Trial of High‐Dosage Antioxidants in an Attempt to Slow the Progression of the Illness , 1989, Annals of the New York Academy of Sciences.

[47]  B. Halliwell.  Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? , 1989, Acta neurologica Scandinavica. Supplementum.

[48]  P. Riederer,et al.  Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.

[49]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[50]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[51]  J. Langston,et al.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. , 1989, Science.

[52]  J. Bormann.  Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. , 1989, European journal of pharmacology.

[53]  L. Golbe.  Long‐term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease , 1989, Neurology.

[54]  M. Naoi,et al.  A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. , 1989, Biochemical and biophysical research communications.

[55]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[56]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[57]  M. Naoi,et al.  Oxidation of N‐Methyl‐1,2,3,4‐Tetrahydroisoquinoline into the N‐Methyl‐Isoquinolinium Ion by Monoamine Oxidase , 1989, Journal of neurochemistry.

[58]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[59]  T. Niwa,et al.  Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. , 1988, Journal of chromatography.

[60]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[61]  Y. Mizuno,et al.  Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain , 1988, Journal of the Neurological Sciences.

[62]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[64]  T. Saitoh.  Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl , 1988, Journal of the Neurological Sciences.

[65]  S. Ohta,et al.  TETRAHYDROISOQUINOLINE AND 1-METHYL-TETRAHYDROISOQUINOLINE ARE PRESENT IN THE HUMAN BRAIN: RELATION TO PARKINSON’S DISEASE , 1987 .

[66]  J. Olney,et al.  Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. , 1987, European journal of pharmacology.

[67]  E. Hall,et al.  A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. , 1987, The Journal of pharmacology and experimental therapeutics.

[68]  N. Sone,et al.  Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium Ion on Activities of the Enzymes in the Electron Transport System in Mouse Brain , 1987, Journal of neurochemistry.

[69]  T. Niwa,et al.  Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.

[70]  P. Dickson,et al.  Distribution of transferrin synthesis in brain and other tissues in the rat. , 1987, The Journal of biological chemistry.

[71]  M. Eichelbaum,et al.  Evidence for polymorphic oxidation of sparteine in Japanese subjects. , 1987, British journal of clinical pharmacology.

[72]  Y. Mizuno,et al.  Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[73]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[74]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[75]  R. Carelli,et al.  Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion , 1986, Neuropharmacology.

[76]  R. Ramsay,et al.  Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.

[77]  V. Yong,et al.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.

[78]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[79]  R. Clavier,et al.  Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.

[80]  E. Melamed,et al.  Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine andl-DOPA , 1985, Brain Research.

[81]  J. Langston,et al.  Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum , 1985, Neuroscience Letters.

[82]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[83]  C. Pert,et al.  Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[84]  K. Chiba,et al.  Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. , 1985, Biochemical and biophysical research communications.

[85]  E. Neafsey,et al.  β-Carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): Endogenous factors underlying idiopathic parkinsonism? , 1985, Neuroscience Letters.

[86]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[87]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[88]  A. Kahn,et al.  Expression of the transferrin gene during development of non-hepatic tissues: high level of transferrin mRNA in fetal muscle and adult brain. , 1984, Biochemical and biophysical research communications.

[89]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[90]  M. Tarczy,et al.  Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease , 1983, Acta neurologica Scandinavica. Supplementum.

[91]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[92]  M. Greaves,et al.  The transferrin receptor , 1982 .

[93]  F. Sanger,et al.  Sequence and organization of the human mitochondrial genome , 1981, Nature.

[94]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[95]  M. V. Van Woert,et al.  Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.

[96]  H. Akita,et al.  Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain. , 1972, Arzneimittel-Forschung.

[97]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.

[98]  P. Leigh,et al.  Erratum: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease (The Lancet, vol. 339/8806 (1375-1377)) , 1992 .

[99]  S. Orrenius,et al.  Role of calcium in toxic and programmed cell death. , 1991, Advances in experimental medicine and biology.

[100]  S. Fahn,et al.  Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats , 1991, Movement disorders : official journal of the Movement Disorder Society.

[101]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[102]  小島 孝彦.  3-amino-1-methyl-5H-pyrido[4,3-6]indole (Trp-P-2) and other heterocyclic amines as inhibitors of mitochondrial monoamine oxidases separated from human brain synaptosomes , 1990 .

[103]  D. Choi,et al.  The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. , 1990, Annual review of neuroscience.

[104]  J. Olney,et al.  Excitotoxic amino acids and neuropsychiatric disorders. , 1990, Annual review of pharmacology and toxicology.

[105]  S. Ohta,et al.  Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. , 1990, Life sciences.

[106]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[107]  S. Ohta,et al.  Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. , 1988, Life sciences.

[108]  A. Cesura,et al.  Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. , 1988, Pharmacological research communications.

[109]  E. Carafoli.  Intracellular calcium homeostasis. , 1987, Annual review of biochemistry.